MTT assay protocols.
The EC 50 values reported in Table 2 were obtained using a standard 4 day MTT cell growth assay, as described in reference 20.
DMPK methods.
The tissue distribution data reported in Table 1 was generated using standard LC-MS/MS bioanalytical methods for the test compounds, performed in the M. Cameron laboratory at Scripps FL.
The appropriate parent and daughter ion pairs were determined for each molecule using direct infusion. In vivo PK was assessed using Sprague Dawley rats. All procedures are IACUC-approved and the Scripps FL vivarium is fully AAALAC-accredited. Tissue levels: Compounds were dosed at 20mg/kg IP, using solutions of 1 mg/mL in a vehicle of 10:10:80 DMSO:Tween80:water. At the predetermined time points, animals were humanely sacrificed and the indicated tissues were collected, mixed with organic solvent, and a probe tip sonicator was used to break up the tissue. Samples were analyzed by LC-MS/MS. Plasma drug levels are determined against standards made in plasma; tissue samples are compared to standards made in blank tissue matrix.
Expression profiling analysis.
Protein expression levels of the MCT transporter isoforms were analyzed, as described in reference 20. As shown in 
Scheme 1 chemistry methods.
Compounds in Scheme 1 (19-27) were prepared as per AstraZeneca's methods, 19 with modifications previously published from our labs. [25] [26] Intermediate halides required in the alkylation step were synthesized in-house by the published synthetic procedures. (m, 1H), 0.92 ppm (dd, J = 6.6, 2.8 Hz, 6H); 13 C NMR (CDCl 3 , 100 MHz) δ 141. 6, 114.3, 71.5, 46.2, 24.5, 23.0, 22.3 ppm; FT-IR (neat, cm -1 ) 3338.9, 2955 .7, 2925 .8, 2870 .8, 1644 .9, 1468 .8, 1423 .8, 1384 .8, 1367 .8, 1308 .9, 1152 .8, 1091 .8, 1055 .8, 1016 . Note: alcohol 20 is appreciably volatile, so care must be taken while evaporating the solvents after workup. 0, 150.9, 119.4, 69.4, 51.7, 45.7, 24.5, 23.1, 22.1 ppm; FT-IR (neat, cm -1 ) 3441.9, 2955 .7, 2870 .8, 1724 .6, 1704 .5, 1658 .7, 1467 .8, 1436 .7, 1385 .8, 1367 .8, 1304 .6, 1276 .6, 1194 .7, 1168 .5, 1078 .7, 1035 .8 cm -1 . 199.5, 166.1, 139.8, 130.2, 52.3, 50.5, 24.7, 22.5 ppm; FT-IR (neat, cm -1 ) 2957 .7, 2873 .8, 1729 .5, 1698 .5, 1466 .8, 1436 .7, 1368 .7, 1298 .5, 1272 .5, 1196 .6, 1171 .5, 1113 .8, 1062 .7, 1027 5, 145.6, 120.2, 116.5, 115.6, 42.5, 38.0, 28.0, 22.7 ppm; 3164.9 (br), 2956.8, 2865.9, 1777.9, 1729.7, 1630.7, 1582.7, 1523.8, 1464.8, 1367.7, 1250.8, 1167.8, 1094.8, 1069.8, 880.9, 763.7, 698. 9, 148.0, 144.2, 121.3, 118.6, 117.7, 114.3, 86.6, 42.2, 37.8, 27.8, 22.6 ppm; 3411. 9, 2963.8, 2870.9, 1746.6, 1659.6, 1595.8, 1522.8, 1476.8, 1459.8, 1389.7, 1369.7, 1335.8, 1351.8, 1319.8, 1290.7, 1273.5, 1257.6, 1144.5, 1101.6, 1081.7, 986.6, 840.7, 768.6 123.2, 121.8, 115.8, 112.6, 61.1, 42.1, 37.7, 32.9, 32.4, 27.9, 25.9, 22.7, 18.3, -5 .2 ppm; FT-IR (neat, cm -1 ) 3128. 8, 2953.7, 2928.7, 2856.7, 1621.5, 1579.6, 1502.7, 1462.7, 1439.8, 1342.6, 1253.7, 1096.5, 1062.7, 1005.7, 939.7, 832.4, 772.4, 697.6 
Data for ketone 22:

Scheme 2 chemistry methods.
Bromide 29 was prepared following the methods shown in reference 21.
Compound 30. Compound 30 was desilylated under standard conditions (1.2 eq. TBAF, THF, 88%) to give compound 7, which was purified by column chromatography on silica gel using an appropriate To N-phthaloyl 1-amino-4-pentyne (43 mg, 0.20 mmol) in a minimal amount (~1 mL) of degassed anhydrous pyrrolidine in a small pressure tube was added the bromide 30 (100 mg, 0.16 mmol), also 7 in a minimal amount of degassed anhydrous pyrrolidine. Pd(Ph 3 P) 4 (0.15 eq) was then added. The tube was sealed and the solution was heated to 80 o C for 8 h, cooled to rt, and concentrated under vacuum to give the crude coupled material, which was purified by preparative HPLC to give 51 mg of A sample of this protected form of compound 9 (5.2 mg, 0.006 mmol) was dissolved in 1 mL of 4M HCl in dioxane. The mixture was stirred at rt for 6 h, diluted with water, extracted with ethyl acetate, and the organic layers were dried, filtered, and concentrated in vacuo. An analytically pure sample of compound 9 was thus obtained (3.8 mg, 97% To alkyne 31 (83 mg, 0.24 mmol) in a minimal amount of degassed anhydrous pyrrolidine (~1 mL) in a small pressure tube was added bromide 7 (100 mg, 0.16 mmol), also in a minimal amount of degassed anhydrous pyrrolidine (~1 mL). Pd(Ph 3 P) 4 (0.15 eq) was then added. The tube was sealed and the solution was heated to 80 o C for 6 h, cooled to rt, and concentrated under vacuum to give the crude coupled material, which was purified by preparative HPLC to give 55 mg of the coupled product, the protected form of compound 10 with an OTBDMS group and an N-Boc group present Alkylation step (a) -To an oven dried 100 mL round bottom flask equipped with a stir bar was added sodium hydride (1.2 eq) and anhydrous DMF (10 mL). The flask was flushed with argon for 5 min and simultaneously was cooled in an ice bath. To a scintillation vial was added 27 (1.0 eq) in DMF (5 mL). This solution was deoxygenated by bubbling with argon for 5 min, then it was added to the reaction mixture by cannula and the mixture was allowed to stir at 0 o C for 2h. In a separate vial, additional halo heterocycle (1.1 eq) was dissolved in anhydrous DMF (5 mL), deoxygenated by bubbling argon for 5 min, and then added to the reaction mixture drop-wise. The resultant mixture was allowed to stir overnight, thereby warming to rt. After confirming the completion of the reaction by LCMS and TLC, it was quenched with aq. NH 4 Cl, extracted with ethyl acetate, the organic layer washed with water and brine, dried over Na 2 SO 4 , filtered, and evaporated to give a crude solid. [A part of this crude solid (10%) was used for deprotection of TBDMS and the remaining part was (90%) was used for next step]. Yields for compounds 32-35 ranged from 68-81%.
General procedure for the Buchwald-Hartwig coupling step (c) -The crude solid (1.0 eq) obtained in step (a) above was dissolved in toluene (5 mL) in a sealable microwave reaction vial. To this mixture was added Pd(OAc) 2 (0.005 eq), BiNAP (0.01 eq), NaOtBu (1.5 eq) and 1,5-diaminopentane (5 eq). The solution was degassed by bubbling with argon for 5 min, the vessel was sealed, and then it was subjected to microwave irradiation for 4 h at 100 °C. LCMS analysis confirmed the completion of the reaction. The reaction mixture was then filtered through a pad of Celite ® , concentrated, and was purified using flash chromatography using a solvent system of 10%
MeOH in dichloromethane, containing 0.1% NH 4 OH each. In some cases, 20% MeOH was also required. After collecting the desired fractions, the pure product was isolated and analyzed by LCMS and 1 H NMR, after which the sample was divided appropriately to perform TBDMS deprotection reactions and coupling chemistry. Yields for compounds 40-43 ranged from 42-77%.
General procedure for the amide coupling step (d) -
The pure compound obtained in step (c) (1 eq) was dissolved in DMF (5 mL) and to it was added coupling agent HATU (1.2 eq), diisopropylethyl amine (4 eq), Boc-Gln-OH (1.2 eq) and allowed to stir overnight. LCMS analysis confirmed desired mass of product and completion of the reaction, thus the mixture was quenched with sat. NH 4 Cl solution. The mixture was extracted with ethyl acetate. The combined organic layers were then washed with water and brine, dried over sodium sulfate, filtered and evaporated to give a crude oil.
General procedure for silyl deprotection in Scheme 3, conversion (b) and the final reaction of conversion (d)
Small amounts (~10-20 mg) of compounds that were obtained in steps a, c and d above were then subjected to deprotection using HCl to give compounds 11-14, and 15-19 shown in Scheme 3. In the general procedure, the small quantity of the TBDMS-protected and/or BOC-protected starting material was dissolved in THF (2 mL) and to this was added 4.0 M HCl in 1,4-dioxane, 3 mL. The reaction mixture was allowed to stir for 2-5 h, when LCMS analysis confirmed the completion of the reaction.
Solvents were then evaporated and the crude material obtained was subjected to purification via preparative HPLC. The desired fractions corresponding to target compounds were isolated, lyophilized, analyzed and finally submitted for assays of MCT1 inhibition. The compounds obtained were white or off-white solids after lyophilization and they were obtained in 29-53% yield for the coupling and deprotection steps. In certain cases, quantities isolated were only sufficient to be characterized by 1 H and HRMS, as 13 C NMR data acquisition was not possible at such low concentrations.
Characterization data (Scheme 3). 
